COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation (ALIGN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01740583
Recruitment Status : Unknown
Verified October 2016 by Mitralign, Inc..
Recruitment status was:  Active, not recruiting
First Posted : December 4, 2012
Last Update Posted : October 17, 2016
Information provided by (Responsible Party):
Mitralign, Inc.

Brief Summary:
The purpose of this study is to test the safety and device performance of the Mitralign system ("MPAS") to treat functional mitral valve regurgitation.

Condition or disease Intervention/treatment Phase
Mitral Valve Regurgitation Device: percutaneous annuloplasty Not Applicable

Detailed Description:
The ALIGN study is a single arm, prospective study. The objective of the study is to investigate the safety and performance of a catheter-based plication device intended to reduce the circumference of the dilated mitral valve. The study will enroll up to 50 subjects from up to 5 sites (Paraguay, Columbia, Dominican Republic, Brazil, and India) who will be followed for 36 months post index procedure. Enrollment is defined at the time the study device is inserted into the body and patients will be followed at 30 days, and Months 6, 12, 24 and 36 post index procedure.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Feasibility Study of the Mitralign Annuloplasty System for the Treatment of Chronic Functional Mitral Valve Regurgitation
Study Start Date : November 2012
Estimated Primary Completion Date : January 2017
Estimated Study Completion Date : November 2017

Arm Intervention/treatment
Experimental: annuloplasty
All patients will receive treatment with the Mitralign Percutaneous Annuloplasty System (MPAS).
Device: percutaneous annuloplasty
plication of the mitral valve annulus

Primary Outcome Measures :
  1. Major Adverse Events (MAE) [ Time Frame: within 30 days post procedure ]
    MAE defined as occurrence of any of the following: Mitral valve-related surgery/intervention, myocardial infarction, cardiac tamponade, stroke, device and/or procedure-related death

Secondary Outcome Measures :
  1. Echocardiographic Outcomes [ Time Frame: at 6 months ]
    Freedom from an increase in ventricular diameter

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Structurally normal mitral valve
  • At least Grade 2 mitral regurgitation
  • Left ventricular ejection fraction not less than 20% and not greater than 45%
  • Left ventricular end diastolic diameter not less than 5.0 cm and not greater than 7.5 cm

Exclusion Criteria:

  • Pregnant or lactating female
  • Mitral stenosis
  • Mod/severe aortic stenosis or regurgitation
  • Mod/severe tricuspid stenosis or regurgitation
  • Endocarditis
  • Previous mitral valve repair or MV replacement
  • Bioprosthetic or mechanical aortic valve
  • Known unstable angina or MI within 30 days prior to procedure
  • CVA within past 6 months
  • Known contraindications to blood transfusion, contrast dye, DAPT

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01740583

Layout table for location information
Clinica CardioVID
Medellin, Antioquia, Colombia
Antonio Dager, MD
Valle del Cauca, Cali, Colombia
Bordeaux Heart University Hospital
Bordeaux-Pessac, France, 33604
Clinique Pasteur
Toulouse, France, 31076
Sanatorio Italiano
Asuncion, Paraguay
American Heart of Poland S.A.
Bielsko-Biala, Poland, 43-316
Centrum Medyczne HZP
Poznan, Poland, 61-485
Instytutem Kardiologii
Warsaw, Poland, 04-628
Sponsors and Collaborators
Mitralign, Inc.
Layout table for investigator information
Principal Investigator: Adrian Ebner, M.D. Sanatorio Italiano (The Italian Hospital)
Layout table for additonal information
Responsible Party: Mitralign, Inc. Identifier: NCT01740583    
Other Study ID Numbers: CLPR-007
First Posted: December 4, 2012    Key Record Dates
Last Update Posted: October 17, 2016
Last Verified: October 2016
Keywords provided by Mitralign, Inc.:
mitral valve, regurgitation, annuloplasty
Additional relevant MeSH terms:
Layout table for MeSH terms
Mitral Valve Insufficiency
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases